This is the authors' abstract. We don't add key points for this paper.
Invariant natural killer T (iNKT) cells play a role in preventing graft-versus-host disease (GVHD) in bone marrow transplantation (BMT), but it is not known whether and how the NKT10 and NKT17 subsets prevent GVHD. Here, we investigated the anti-GVH effects of iNKT cell subsets in a major-MHC mismatched murine BMT in which BALB/c recipients (H-2 d ) received grafts from C57BL/6 (H-2 b ) donors. The graft consisted of bone marrow and T cells from Traj18 KO (iNKT cell deficient) mice supplemented with iNKT cells purified from donors with various genetic alterations of iNKT subsets. First, NKT17-enriched CD4 - iNKT cells showed anti-GVH effects similar to those of NKT2-enriched CD4 + iNKT cells, while NKT2/17 deficient iNKT cells failed to prevent GVHD, suggesting that either or both of these subsets have anti-GVH function. Furthermore, IL10 KO iNKT cells completely lost their protective effects, whereas IL17AFD KO iNKT cells demonstrated partially abrogated anti-GVH effects, supporting the indispensable role of NKT10 in preventing GVHD after BMT. Using IL-17 fate-mapping mice, we demonstrated that NKT17 can trans-differentiate into NKT10 in vitro after antigenic stimulation under T regulatory type 1 (Tr1)-promoting conditions. In conclusion, NKT10 plays a role in preventing GVHD in BMT and NKT17 may contribute to the anti-GVH effects via trans-differentiation into NKT10.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Trujillo‐Ocampo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: